"Today, the vaccine is produced in fifteen different countries, with jabs having been delivered in over 170 countries. The Anglo-Swedish drugmaker initially rebuffed pressures to make a profit on its 2 billion vaccines, while its rivals netted billions in revenues. This year, AstraZeneca is set to make a loss on the vaccine of 3 cents per share, according to the Financial Times."
